Anti-Cancer

LENVATINIB (BDFOIE) Tablet

$297.00

Lenvatinib (BDFOIE) Tablet represents a significant therapeutic advance in the management of hepatocellular carcinoma, offering targeted therapy that can improve outcomes and quality of life for patients facing this challenging disease. With careful monitoring, patient education, and access to treatment, lenvatinib holds promise in reshaping the landscape of HCC care and providing hope for those affected by this condition.

Strength	Choose an option4mg10mg
	Clear

Quantity

LENVATINIB (BDFOIE) Tablet quantity

Add to cart

Sku:

N/A

Tag:

LENVATINIB BDFOIE

Description

Lenvatinib (BDFOIE) Tablet stands as a beacon of hope in the realm of oncology, offering a potent therapeutic option for individuals confronting various cancers, particularly hepatocellular carcinoma (HCC), the most common form of liver cancer. This oral medication, encapsulating the active ingredient lenvatinib, represents a significant advancement in the treatment landscape, providing renewed prospects for improved outcomes and enhanced quality of life.

Key Features :

Targeted Therapy: Lenvatinib is a multikinase inhibitor that targets multiple receptors involved in tumor angiogenesis, proliferation, and metastasis. By inhibiting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and other key pathways, lenvatinib effectively impedes tumor growth and progression.

Treatment of Hepatocellular Carcinoma (HCC): Lenvatinib is indicated for the treatment of patients with unresectable HCC who have not received prior systemic therapy. It offers a valuable treatment option for individuals facing this aggressive malignancy, particularly those who are not candidates for surgery or transplantation.

Oral Administration: Administered orally once daily, Lenvatinib BDFOIE Tablet is typically taken on an empty stomach, at least one hour before or two hours after a meal. Patients should adhere to the prescribed dosing schedule and follow healthcare provider instructions meticulously.

Efficacy: Clinical trials have demonstrated the efficacy of lenvatinib in prolonging overall survival and progression-free survival in patients with unresectable HCC, both as a first-line treatment and in patients who have progressed on prior systemic therapy.

Side Effects: Common side effects of lenvatinib may include hypertension, fatigue, diarrhea, decreased appetite, and weight loss. Patients should be closely monitored for adverse reactions, and dose adjustments or supportive care measures may be necessary to manage side effects.

In conclusion, Lenvatinib (BDFOIE) Tablet represents a significant therapeutic advance in the management of hepatocellular carcinoma, offering targeted therapy that can improve outcomes and quality of life for patients facing this challenging disease. With careful monitoring, patient education, and access to treatment, lenvatinib holds promise in reshaping the landscape of HCC care and providing hope for those affected by this condition.

Additional information